AU604214B2 - An improved heat-shock control method and system for the production of competent eukaryotic gene products - Google Patents
An improved heat-shock control method and system for the production of competent eukaryotic gene products Download PDFInfo
- Publication number
- AU604214B2 AU604214B2 AU62860/86A AU6286086A AU604214B2 AU 604214 B2 AU604214 B2 AU 604214B2 AU 62860/86 A AU62860/86 A AU 62860/86A AU 6286086 A AU6286086 A AU 6286086A AU 604214 B2 AU604214 B2 AU 604214B2
- Authority
- AU
- Australia
- Prior art keywords
- gene
- sequence
- heatshock
- promoter
- deoxynucleotides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108090000623 proteins and genes Proteins 0.000 title claims description 161
- 238000000034 method Methods 0.000 title claims description 32
- 238000004519 manufacturing process Methods 0.000 title claims description 24
- 230000001976 improved effect Effects 0.000 title description 3
- 239000013612 plasmid Substances 0.000 claims description 89
- 210000004027 cell Anatomy 0.000 claims description 53
- 239000012634 fragment Substances 0.000 claims description 45
- 102000004169 proteins and genes Human genes 0.000 claims description 42
- 230000014509 gene expression Effects 0.000 claims description 38
- 108020004414 DNA Proteins 0.000 claims description 24
- 108091035707 Consensus sequence Proteins 0.000 claims description 20
- 239000002773 nucleotide Substances 0.000 claims description 20
- 125000003729 nucleotide group Chemical group 0.000 claims description 20
- 238000012986 modification Methods 0.000 claims description 19
- 230000004048 modification Effects 0.000 claims description 19
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 claims description 18
- 101150074155 DHFR gene Proteins 0.000 claims description 17
- 230000014616 translation Effects 0.000 claims description 16
- 230000014621 translational initiation Effects 0.000 claims description 14
- 238000012217 deletion Methods 0.000 claims description 12
- 230000037430 deletion Effects 0.000 claims description 12
- 238000013519 translation Methods 0.000 claims description 12
- 238000003780 insertion Methods 0.000 claims description 9
- 230000037431 insertion Effects 0.000 claims description 9
- 108700007698 Genetic Terminator Regions Proteins 0.000 claims description 7
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims description 7
- 230000006698 induction Effects 0.000 claims description 7
- 230000001939 inductive effect Effects 0.000 claims description 7
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 6
- 108091026890 Coding region Proteins 0.000 claims description 4
- 241000255601 Drosophila melanogaster Species 0.000 claims description 3
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims description 3
- 108700009124 Transcription Initiation Site Proteins 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 239000003999 initiator Substances 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 4
- 108091081024 Start codon Proteins 0.000 claims 3
- 239000003550 marker Substances 0.000 claims 3
- 108020004511 Recombinant DNA Proteins 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 105
- 102000002265 Human Growth Hormone Human genes 0.000 description 100
- 239000000854 Human Growth Hormone Substances 0.000 description 97
- 230000000694 effects Effects 0.000 description 27
- 230000035939 shock Effects 0.000 description 25
- 238000010276 construction Methods 0.000 description 21
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 20
- 238000002474 experimental method Methods 0.000 description 18
- 210000000287 oocyte Anatomy 0.000 description 14
- 238000011534 incubation Methods 0.000 description 13
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- 238000001890 transfection Methods 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 9
- 230000000977 initiatory effect Effects 0.000 description 8
- 239000000284 extract Substances 0.000 description 7
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 6
- 230000001086 cytosolic effect Effects 0.000 description 6
- 238000001114 immunoprecipitation Methods 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 5
- 101150031823 HSP70 gene Proteins 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 230000010474 transient expression Effects 0.000 description 5
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 4
- 108091028026 C-DNA Proteins 0.000 description 4
- 241000282693 Cercopithecidae Species 0.000 description 4
- 108010092160 Dactinomycin Proteins 0.000 description 4
- 101100125027 Dictyostelium discoideum mhsp70 gene Proteins 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
- 101150052825 dnaK gene Proteins 0.000 description 4
- 229960004452 methionine Drugs 0.000 description 4
- 108091027963 non-coding RNA Proteins 0.000 description 4
- 102000042567 non-coding RNA Human genes 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 241000269370 Xenopus <genus> Species 0.000 description 3
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 229960000640 dactinomycin Drugs 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000004114 suspension culture Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 241001131785 Escherichia coli HB101 Species 0.000 description 2
- 108050001049 Extracellular proteins Proteins 0.000 description 2
- 102000002464 Galactosidases Human genes 0.000 description 2
- 108010093031 Galactosidases Proteins 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- YOYAIZYFCNQIRF-UHFFFAOYSA-N 2,6-dichlorobenzonitrile Chemical compound ClC1=CC=CC(Cl)=C1C#N YOYAIZYFCNQIRF-UHFFFAOYSA-N 0.000 description 1
- 101710091601 21 kDa protein Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101100129088 Caenorhabditis elegans lys-2 gene Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000004214 DNA polymerase A Human genes 0.000 description 1
- 108090000725 DNA polymerase A Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 101001077660 Homo sapiens Serine protease inhibitor Kazal-type 1 Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 101000966481 Mus musculus Dihydrofolate reductase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 241001045988 Neogene Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102100025144 Serine protease inhibitor Kazal-type 1 Human genes 0.000 description 1
- 241001080024 Telles Species 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 241000902900 cellular organisms Species 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 101150091879 neo gene Proteins 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 108091033319 polynucleotide Chemical group 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Chemical group 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Description
S- ill li m PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION i F 4 [International Bureau INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (51) International Patent Classification 4 (11) International Publication Number: WO 87/ 00861 C12N 15/00 Al1 (43) International Publication Date: 12 February 1987 (12.02.87) S (21) International Application Number: PCT/EP86/00451 (74) Agents: DOUSSE, Blasco et al.; 7, route de Drize, CH- 1227 Carouge (CH).
(22) International Filing Date: 29 July 1986 (29.07.86) (81) Designated States: AT (European patent), AU, BE (Eu- (31) Priority Application Number: 85810354.2 (EP) ropean patent), CH (European patent), DE (European patent), DK, FR (European patent), GB (Euro- (32) Priority Date: 31 July 1985 (31.07.85) pean patent), IT (European patent), JP, LU (European patent), NL (European patent), NO, SE (Euro- (33) Priority Countries: CH, et al. pean patent), US.
(71) Applicant (for all designated States except US): BAT- Published TELLE MEMORIAL INSTITUTE [US/CH]; 7, route With international search report.
de Drize, CH-1227 Carouge Before the expiration of the time limitfor amending the claims and to be republished in the event of the receipt (72) Inventors; and of amendments.
Inventors/Applicants (for US only) BROMLEY, Peter [GB/CH]; 26, chemin du Pont de Ville, CH-1224 Chene-Bougeries DREANO, Michel [FR/CH]; A. 0 I P i' chemin des Bouvreuils, CH-1234 Vessy VO- ELLMY, Richard [CH/US]; 7240 SW, 124th Street, Miami, FL 33156 r hGH 21 18.4 Mw (KDa) (57) Abstract 25.7 14.3 In the 70 KDa hsp promoter, modifications brought about to the 5' and 3' non-translated sequences, including M the insertion or deletion of nucleotides and the number of 18 heat shock consensus sequence elements present in the proximal region of a heat shock gene promoter critically influ- 16 ences promoter activity. Sequence variants in translation in- 0 itiation and 3'-non-translated regions have been shown to improve levels of induced protein production. Mutant 14 promoters were constructed that have higher maximal activities than the natural parent promoter in heat-shocked cells.
These mutant promoters are also expressed at high levels at 12 a temperature below that required for optimal induction of S the natural heat-shock genes. These results are of practical interest for attempts to use heat-shock promoters for the inducible production of eukaryotic proteins of medical or in- S dustrial importance. 8 6 4 MaEE.
I _r 11 O 87/00861 PCT/EP6/00451 1 AN IMPROVED HEAT-SHOCK CONTROL METHOD AND SYSTEM FOR THE PRODUCTION OF COMPETENT EUKARYOTIC GENE PRODUCTS.
INTRODUCTION
The use of and the advantages of the heat-shock expression elements for the production of gene-products ot interest under heat-shock control in a variety ot cell types, have previously been described DREANO et al. gene (1986), in press.
This technique has the intr'insic advantages as a eukaryotic expression system of having an efficient, general and highly inducible character.
These factors are of considerable interest for the commercial production of proteins of pharmaceutical and other interest, particularly where these proteins are complex, modified, unstable or potentially toxic to the producer cell.
The natural heat-shock system in the living cell performs, amongst other roles, a complex and as yet poorly defined protective function; the nature of heat-shock transcriptional and translational heat-shock control elements have presumably evolved in a fashion leading to an optimization of the physiological role of their associated gene products. The characteristics of production and stability ot heat-shock messenger RNA's and proteins are specific to their physiological roles, and are thus not necessarily those optimally desired for the heat-shock controlled production of proteins of interest. Since a number ot sequence domains involveo in heatshock promotor regions as well as heat-shock-RNA leaders have been described see e.g. AMIN et al., Mol. Cell. Biol. 5, (1985), 197-203, it appeared to us that sequence modifications in the non-coding heat-shock control constructions could lead to advantageous variant sequence constructs for the production of proteins of interest. Also, for practical purposes it may also be advantageous to lower the threshold of temperature or of other stresses for high level expression: such a modification may render the induction of genes of interest under heat-shock control more economical in situations of large scale culture. Moreover, producer cells exposed to a lesser dearee of stress may be better capable of supporting high levels of protein synthesis without damaging effects possibly arising from stress.
In addition, the heat-shock controlling elements have also been selected from the human genome to improve compatibility between the expression system involved and the selected host-cell machinery.
I
WO 87/00861 PCT/EPS6/00451 2 SUMMARY OF THE INVENTION The modifications which led to the method of the invention as summarized by claim 1 can be mainly of three kinds to be applied independently or in combination, i.e. nucleotide insertion, nucleotide deletion and nucleotide substitution. Insertion and deletion may include single nucleotides or polynucleotide fragments. The 3' and/or 5' non-translated sequences can be derived from hsp genes, foreign genes or synthetic DNA such as linkers and adapters and involve ribosome binding an( translation initiation sites sequences adjacent to the ATG initiator. Some modifications also relate to the hs consensus sequence identified by PELHAM et al, Trends Genet 1 (1985), 31-34, in the hsp 70KDa of Drosophila Melanogaster, of formula CnnGAAnnTTCnnG; this sequence proposition is by no means exclusive, and is the proposal of these authors, based on the data available to them at the time. As our data base of heat-shock consensus sequences expands, we may expect changes in the statistical consensus sequence that can be described.
In some embodiments of the invention, the number of such sequences in the non-translated region has been increased over that normally present in the hsp70 KDa gene; in other embodiments, the position of said sequences relative to each other and to other promoter elements has been modified.
The "heat shock gene control element" is defined as being composed of both a heat-shock promotor enabling control of DNA transcription into RNA, and a heat-shock RNA leader sequence influencing translational control into protein. It has generally been observed that -the activity of a heat-shock promotor is independent of cell type, while the specific heat-shock translational control is largely dependent on the homology of the RNA leader and the cell or organism employed for expression.
The invention provides tor a method for enhancing and inducing the expression of a gene, coding for the production of a gene product (comprising a sequence of amino acids, a protein), under the control of a heat shock gene control element of the type comprising a heat shock gene translational control element, a heat shock gene promoter sequence and leader sequence, said method comprising assembling sequences of deoxynucieotides into a fragment insertable into a plasmid and in a 5' to 3' direction comprising, in order, a heat shock gene promoter sequence, a transcription start site sequence, a transcribed but not translated leader sequence for translational control in i '~L WO 87/00861 PCT/EP86/0045 1 protein production, a consensus sequence coding for translation initiation, a gene sequence coding for production of a protein, and a nontranslated sequence at the 3' end, the heat shock gene promoter sequence comprising not more than 1500 deoxynucleotides and from 2 to 12 heat shock promoter consensus regions, each said heat shock promoter consensus region comprising not more than 11 deoxynucleotides of formula substantially approaching 1 2 3 4 5 6 7 8 9 10 11 C G) A) G n 1 n 2 n 3 n 4 T T C such that at least 5 deoxynucleotides in the formula in positions 3 to 4, and 9 to 11, are substantially conserved from heat shock promoter'consensus region to heat shock promoter consensus region, and wherein each n is independently selected from A, T, C or G, the consensus sequence coding for translation initiation comprising not more than 20 deoxynucleotides and substantially comprising the formula -4 -3 -2 -1 1 2 3 4 nx C C A C C A T G G n(yx) wherein CC and CC predominates in positions and -5 at an occurence frequency of at least 25 wherein A predominates in position -3 at an occurence frequency of about 80 wherein ATG predominates in positions 1, 2 and 3 at an occurence frequency of about 90 wherein G predominates in position 4 at an occurence frequency of 40-60 wherein each n is independently selected from A, T, C, or G, wherein y is selected from 0 to 11, wherein x is selected from 0 to y, the nontranslated sequence at the 3' end comprising nontranslated gene sequences of not more than 3000 deoxynucleotides, a terminator sequence, and a poly A addition sequence.
inserting the fragment into a plasmid so as to form a heat shock gene promoter controlled plasmid, inserting the heat shock gene promoter controlled plasmid into a eukaryotic cell competent in the expression of the gene coding tor the production of the protein, stressing the eukaryotic cell to induce expression of the gene coding for the production of the protein.
It is to be understood in step 1 above here and in the claims that the order is important for the DNA sequences assembled in the named order, MMW_ J I~ L WO 87/00861 Pc/EP86/00451i 4 however, additional intervening nucleotides can be included between the ordered sequences without detriment.
Preferably the heat shock gene promoter is derived from the heat shock genomic DNA of Drosophilia melanqaster, particularly the genes encoding the kilodalton heat shock proteins.
The heat shock gene control element is composed of both a heat shock promoter enabling DNA transcription into RNA and a heat shock leader sequence influencing translational control of RNA into protein. It has generally been observed that the activity of the heat shock promoter is independent of the specific eukaryotic cell, while heat shock translation is dependent on the homology of the RNA leader and the cellular organism used for its expression.
The RNA leader, the 5' transcribed but not translated leader sequence, is between the transcription start site and the translation start site. The leader can be a heat shock leader enabling translation to occur at heat shock temperature or a leader from another source permitting RNA translation at normal growth temperature.
BRIEF DESCRIPTION OF THE FIGURES The invention will now be described with reference to the drawing in which the symbols defining the DNA sequences are shown, see fig 7.
Fig. la represents plasmid p17, a DNA construction derived from pBR322 and incorporating a human heat-shock control sequence isolated from a human x genomic library (VOELLMY et al., PNAS USA. 82 (1985), 4949-4953).
Fig. lb represents plasmid pSP65 (New England Nuclear Laboratories) comprising a BamH I restriction site within a polylinker fragment Fig. Ic represents plasmid p17 65 JO resulting from insertion of the EcoR I (fill-in)-Hind III fragment from p17 into Pvu II-Hind III sites of pSP Fig. Id represents plasmid p17 JO resulting from Bgl II digestion and partial digestion with BamHI of p17 65 JO and auto ligation of a resulting 3,4 Kb fragment.
Fig. 2a represents plasmid phGH (obtained from Celltech Ltd., Slough, GB) containing a c-DNA fragment of a human growth hormone (hGH).
Fig. 2b represents plasmid pSP hGH resulting from the insertion of a BamH I fragment of phGH into the BamH I site of Fig. 2c represents plasmid p17 hGH resulting from the insertion of a I_ i i 3- I WO 87/00861 PCTT/E P86/00451 Sal I Hind III fragment of pSP hGH in-3 corresponding restriction sites of the polylinker of p17 JO (fig. Id).
Fig. 3a illustrates plasmid p17 hGHA6 resulting from the deletion of six nucleotides in the sequence preceding the hGH initiation of translation site.
Fig. 3b represents plasmid pSV2 dhfr (SUBRAMANI et al., Mol. Cell Biol. 1 (1981), 854-864) containing the mouse dihydrofolate reductase gene under the control of the SV40 early promoter sequence and terminated by the early terminator sequence.
Fig. 3c represents plasmid pl7 hGH dhtra 6 obtained by ligation of a 1.2 Kb EcoRI BamH I fragment of p17 hGH 66 into the BamH I and EcoR I sites of pSV2 dhfr.
Fig. 4a represents plasmid pSV2 NEO (disclosed by SOUTHERN et al., J, Mol. Appl. Genet. 1 (1982), 327-341) containing a neomycin (NEC) resistance gene under the control of the early SV40 promoter and terminated by the early SV40 terminator sequence.
Fig. 4b represents plasmid pSP NEO 9 which results from the ligation of a Pvu II BamH I fragment derived from pSP65 and a fragment resulting from the partial digestion of pSV2 NEO with the same endonucleases (Pvu II BamH I).
Fig. 4c represents plasmid p17 hGH NEO resulting from the ligation of a 1.3 Kb EcoR I fragment derived from pl7hGH (see fig. 2c) with EcoR I linearized pSP NEO 9.
Fig. 5 is an autoradiography of an acrylamide gel electropherogram showing the various protein fractions inducibly expressed in frog oocytes using a selected gene of interest, according to the invention. Lane identification is given below; C means control temperature. Immunoprecipitation is performed with anti-hGH serum.
~i WO 87/00861 PCT/EP86/00451 M Protein markers 1 pl7 lys 2 p17 hGH 3 pl7 hGH 4 p1 7 hQH A 6 pl7 hGH A 6 6 p17 hGH dhtr a 6 7 pl7 hGH dhtr a 6 8 pl7 hGH NEO 9 p 17 hGH NEO p17 lys 11 p 17 hGH 12 p 17 hGH 13 p17 hGH A 6 14 p17 hGH a 6 p 17 hGH dhfr A 6 16 pl 7 hGH dhtr 6 6 17 p 17 hGH-NEO 18 p 17 hGH-NEO HS CYTOPLASM
C
HS
C
HS
C HS HS CULTURE MEDIUM
C
HS
C
HS
C
HS
C
HS
Protein markers Fig. 6 refers to data similar to that illustrated in fig. 5 but genes are expressed in COS (monkey) and CHO (hamster) cells.
lys hGH hGH lys hGH hGH dhfr dhfr dhtr dhfr
COS
COS
COS
CHO
CHO
CHO
The position of protein molecular weight markers (in kilodaltons, KDa) are indicated on the right hand side of the figure.
Fig. 7 is a key to DNA sequence symbols.
Fig. 8 illustrates the base sequences of a region of the Drosophila hsp 70KDa gene including the transcriptional and translational site and the non-transcribed sequences including the promoter with the four consensus region sequences (-49 to -67, -64 to -87, -130 to -195, -191 to -430).
7 WO087/008,51 7 PCT/EP86/0045
I
The plasmids identified in figs la to 4c include the following sequences and restriction sites (see fig. 7) Pla smid Sequences Kb p17 pl7 65 JO p17 JO phGH pSP hGH p17 hGH p17 hGH a6 pSV2 dhfr p17 hGH dhtr 11 2. 6 11 3.0 11 :2.8 11 2.8 11 11 :3.0 11. 2.8 ditto 11 2.3 16 :0.7 11 2.8 16 :0.7 :0.6 11 2.3 14 :1.5 11 2.8 14 :1,5 11 2.8 12 0.7 14 1.5 10 15 1.0 10 2 12 10 3.9 0.1 3.2 ;15 0.1 0.6 ;15 0.1 0.7 0.7 ;15 0.1 0,6 ;12 -0.7 pSV2 N)E0 pSP NE09 13 (promoter) :0.4 13 (terminator):1.6 13 (promoter): 0.4, 13 (terminator):0,7 12 0,7 13 (promoter):0.4 13 (terminator):1.6 13 (promoter): 0.4 13 (terminator):0.7 13 (promoter): 0.4 13 (terminator):0.7 10 0.6 p17 hGH NEG
NI
BI XI
HIIT
R!
SI
B11
PII
Nco I BamH I Xba i Hind !II EcoR I Sal I Bgl II Pvu !I Xi WO 87/00861 PCT/EP86/00451 DETAILED DESCRIPTION OF THE INVENTION In a first embodiment of the invention, a plasmid, p17, derived from pBR322 and containing a functional human hs control element was obtained by screening by plaque hybridization a lambda human genomic library, using as a probe a coding sequence for the Drosophila hsp 70 KDa gene (VOELLMY et al., PNAS USA 82 (1985) 4949-4953). The presence of a functional human hs control element in the DNA isolated in the cloning procedure was determined by sequence analysis as disclosed in EP-A-118 393 and the foregoing VOELLMY et al. (1985) PNAS reference. A restriction fragment containing a 3.15 Kb hs non transcribed sequence and a 115 bp RNA leader was ligated with a Pvu II-Hind III fragment from pSP65 (fig Ib, a commercially available plasmid) to provide plasmid p1765 JO (tig. Ic). A BamH I Bgl II restriction fragment therefrom (3.4 Kb) containing a small 5' non transcribed sequence (0.45 kb) was autoligated to provide plasmid p17 JO (fig. Id).
A human growth hormone c-DNA containing clone (plasmid phGH obtained from Celltech Ltd., Slough, GB, see fig. 2a) was inserted into the polylinker of pSP65 (fig. lb)"to provide plasmid pSP hGH (fig. 2b). Then a Hind III Sal I 0,7 Kb fragment of the latter comprising the hGH sequence was inserted into the corresponding restriction site of the polylinker of pl7 JO to give p17 hGH (fig. 2c); in this construction the hGH sequence is separated from the hs sequence by 27 bp including an ATG triplet before the initiation site. By digestion with Xba I and Nco I and filling in with DNA polymerase large fragment, deletion of six nucleotides immediately preceding the ATG triplet was accomplished, which-was followed by auto-ligation to provide plasmid p17 hGH A 6 (fig. 3a). This plasmid contains the hGH sequence under the control of the human hs promoter, with a RNA leader sequence modified by deletion. This sequence contains one for optimal translation initiation, conforming to the established consensus sequence involving strong eukaryotic translation initiation sites (see for instance M. KOZAK, Nat,'re 308 (1984), 241-246). Indeed, enhancement of the expression of the deletion modified hGH gene in suitable eukaryotic hosts compared to a control involving no deletion was observed. This will be described hereafter.
In a second embodiment, a 1.2 Kb restriction fragment from p17 hGH A 6 containing the hGH gene and the hs sequence was inserted into the BamH I Land EcoR I sites of plasmid pSV2 dhtr (fig. 3b), the latter being obtained as disclosed by SUBRAMANI et al. Mol, Cell Biol. 1 (1981), 854-864. The re- WO 87/00861 PCT/EP86/00451 9 suiting plasmid p17 hGH dhfr 66 (tig 3c) included the hGH sequence under the control of the human hs promoter (6 6 included) and terminated by the late terminator and, secondly, the dhtr gene under the control of the SV40 early promoter (note the inverted reading mode). In this embodiment, the presence of the 3' late untranslated sequence also enhanced expression under stress as will be seen hereafter.
In a third embodiment, a plasmid, pSP NEO 9, (fig. 4b) was constructed from a BamH I-Pvu II restriction fragment of pSV2 NEO (SOUTHERN et al, J.
Mol. Appl. Genet. 1 (1982), 327-341) containing the neomycin-resistance gene under the control of the SV40 early promoter and ended by the early terminator (including the poly-A addition site), and a corresponding restriction fragment from pSP 65. Digestion of pl7 hGH (fig. 2c) with EcoRI provided a 1.3 Kb fragment which was ligated with EcoR I linearized pSP NEO 9 to provide plasmid p17 hGH NEO (fig. 4c). This plasmid contains two transcriptions units: first the NEO gene under the control of the early promoter and, second, the hGH gene under the control of the hs promoter with an unmodified initiation sice but terminated by the early terminator. The presence of the 3' untranslated sequence also enhanced the expression of the hs controlled hGH gene in suitable host cells under stress.
Expression experiments and results will now be discussed hereunder; further construction embodiments will be disclosed hereafter.
In a first series of expression experiments the transient expression system of injection of DNA constructs into Xenopus oocyte nuclei were used as previously described (VOELLMY and RUNGGER,- PNAS USA 79, (1982), 1776- 1780) to analyse the controlled synthesis of human growth hormone (hGH).
The plasmid constructions resulting from the aforementioned embodiments were used. In brief, the injected DNA-containing oocytes were subjected to stress (90 minutes at 36 0 C followed by incubation at 21 0 C for 12 hours in the presence of 35 S-labelled methionine (500 pCi/ml); the presence of labelled protein products in either the cytoplasmic extract of the oocytes, or in the suspension media, was determined by immunoprecipitation essentially as previously described (EP-0.118.393); the results obtained are shown in fig. In addition to the protein molecular weight markers indicated in lanes M. two series of analyses of immunoprecipitated proteins are shown; lanes 1-9 indicate the results obtained from the cytoplasmic extracts of the injected oocytes, while the lanes 10-18 show the corresponding results WO 87/00861 0PCT/EPS6/00451 obtained from the suspension media of the same oocytes. The results obtained concerning hGH synthesis are essentially identical -for the two series of analyses, and the results on the secreted, extracellular proteins will be further described in the experimental part.
Lanes 11 and 12 show the results using plasmid pl7 hGH at the control and heat-shock temperatures respectively; lanes 13 and 14, 15 and 16, 17 and 18 are comparable experiments employing plasmids pl7 hGH A6; pl 7 hGH dhfr a6; and pl7 hGH NEO. The results may be summarized with respect to the production of a protein of molecular weight 21 kDa specifically immunoprecipitated by the anti hGH antisera, as follows: The plasmid pl7 hGH, which is an RNA leader fusion construct within the RNA leader sequences derived from the human hsp70 clone and lacking five nucleotides of the human sequence, produces a detectable level of hGH after heat-shock, with no apparent synthesis in the absence of heat-shock.
Plasmid p17 hGH A 6 is a 5'untranslated sequence modification that provides a theoretically stronger translation initiation site; this plasmid is seen to behave in a manner comparable to the previous one in the transient expression assay employed. It should be remembered that both of these plasmid constructions lack a classical 3' end terminator and poly A addition signal. Plasmid p17 hGH NEO incorporates such a 3' modification by the insertion of the neomycin-resistance gene in an inverted mode with respect to the hGH sequences, and this with the unmodified initiation sequence; here a certain degree of increased efficiency of synthesis is observed.
When the two types of 3' and 5' modifications are combined in plasmid construction pl7 hGH dhfr A6, a dramatic increase in expression efficiency of hGH is observed, and this being almost totally under heat-shock control (see lanes 15 and 16, fig. Plasmid pl7 hGH dhfr 6 6 was also used to transfect cultures of COS-1 monkey cells (Gluzman, Cell 23 (1981), 175-182). The expression of human hGH in these cells was analysed using procedures essentially as described (DREANO et al., gene (1986) in press). In this case an induction of 3 hours at 43 0 C followed by incubation at 37 0 C for a further 16 hours in the presence of 35 S-methionine was used. Control cultures that had not been heat-stressed were treated in a parallel fashion; both sets of cell cultures were then processed by immunoprecipitation with anti hGH sera and analyzed on acrylamide gels as described above. The results obtained from analyses of the suspension cultures are shown in fig. 6.
The results obtained from the transfection of COS cells are shown in i L- WO 87/00861 PCJT/EP86/00451 11 lanes 1, 2 and 3, and it can be seen that neither transtection with control DNA followed by a heat-shock (lane or transfection with the optim:,l hGH construct in the absence of a heat-shock (lane give rise to the production and secretion of a 21 KDa protein specifically precipitated by anti-hGH sera. The COS cells transfected with p17 hGH dhfr 6 and submitted to a heat-shock produce a single, major secreted protein band of the expected molecular weight for hGH (see lane An essentially identical result is obtained from the transtection studies using CHO cells (chinese hamster ovary), see fig. 6, lanes 13, 14 and It is therefore demonstrated here that in the technique of directing the synthesis of a heterologous human protein under heat-shock control, relatively limited modifications ot the non-translated sequences employed in the expression constructs can lead to increased levels of production of the gene product of interest. It is evident that the sequence variants that have been employed are examples of those that can be produced using analogous and related techniques. The precise level of action of the new sequence elements has not been determined although, in general, modifications of heat-shock related sequences could be expected to act at the levels of promotor activity, RNA stability, and translational efficiency. Clearly other sequence variants can be produced and may have similar or complementary effects on the optimization of heat-shock control constructs for the production of proteins of interest. It has been demonstrated that the human elements function in an analogous way for the controlled synthesis of a non-heat-shock protein to the elements derived from Drosophila (EP- 0.118.393). In addition, it is demonstrated that the production of a secretable protein, for example human growth hormone, is possible under human heat-shock control, and that this occurs, together with secretion of the protein out of the cell, and this when the same plasmid construction is introduced into frog, monkey cells and others. It may be assumed that the same or similar constructions will permit the production of many proteins including secreted proteins from a large variety of cell types and organisms, including human cells.
The next embodiments concern modifications involving the consensus sequence present in the 5' non-translated region of 70 KDa hs protein genes from Drosophila. This consensus sequence of 14 bp has the formula Cnn GAAnnTTCnnG and has been suggested (PELHAM, Trends Genet 1 (1985), 31-34) between positions -49 and -62 in the 5' nontranscribed region of Drosophila heat-shock protein genes, and which is responsible for the heat-regulated i i WO 87/00861 PCT/E P86/00451 12 expression of the genes when they are present in high numbers of copies in heterologous cell types (PELHAM Cell 30 (1982), 517 528; MIRAULT et al., EMBO J. 1 (1982), 1279 1285). This sequence element is being referred to as the hs consensus sequence.
Experiments by several groups (DUDLER and TRAVERS, Cell 38 (1984), 391 398; AMIN et al., Mol, Cell. Biol. 5 (1985), 197 203; SIMON et al., Cell 40 (1985), 805 817) have suggested that two consensus-like sequences may be mainly responsible for the heat-regulated activity of the Drosophila KDa hsp genes when present in low copy numbers and in homologous cells.
Furthermore, the presence of multiple consensus-like sequences in the promoters of several hs genes has been noted; the promoters of Drosophila KDa hsp genes contain four such sequences in the first 300 bp o- nontranscribed sequence. The four elements reside in areas of the promoters designated here regions 1 through 4. Region 1 extends from -49 to -67, region 2 from -64 to -87, region 3 from -130 to -195 and region 4 from -191 to -430 (see nucleotide sequence of promoter in Fig. 8).
These observations have led to the hypothesis that hs promoter activity and inducibility not only depend on the exact sequences of the hs regulatory elements but also on the number of such sequences and on their positions relative to each other and to other promoter elements. Our findings indeed suggest that both the position and the number of consensus-like sequences have significant effects on promoter function. In those experiments, the test gene, placed under modified hs control sequences of eukaryotic origin was the P -galactosidase gene of bacterial origin.
The constructions to support the above -findings involved 5' promoter deletion mutants (prefix D for Deletion, the numbers after thz prefix refer to the lengths in bp of promoter segments) of the Drosophila 70 KDa hsp- E.
coli P-galactosidase hybrid gene p622c (see AMIN et al., Mol. Cell. Biol. (1985) 197-203 who reported mutant gene D-194 (hybrid gene 622c) as well as D67 (622a) and D50 (622 n).
A first control mutant, IN10, the promoter of which contains aforementioned consensus regions 1 and 2 only was constructed as follows: D87 DNA was digested with BssH II (cuts at ends were filled in by DNA polymerase large fragment, Bgl II linkers (AGATCTAGATCT) were added, the material was double-digested with Hind III/Bgl II and Cla I/Bgl II and then electrophoresed on a 1% low melting agarose gel. A 2.6 Kb Hind IIl/Bgl 11 fragment including region 2 of the promoter of a Dro.sohilia 70 KDa hsp gene and pSVOd vector sequences (MELLON et al., Cell 27, (1981) 279 288), 0000h.
3 WO 87/00861 PCT/E P86/00451 13 including the bacterial and SV40 origins of replication and the ampicillin resistance gene and a 1.2 Kb Cla I/Bgl Il fragment containing region 1 and the RNA leader region of the 70 KDa hsp gene as well as the first one third of the 8-galactosidase-coding sequence were isolated. These two fragments were ligated to a similarly purified 4.8 Kb Cla I/Hind III fragment from D87 which included the remainder of the 8-galactosidase gene, heat--shock gene 3' trailer sequences and a 0.35 kb vector segment (BamH I to Hind III in pSVOd). Transformation of E.coli and identification of recombinant plasmids were carried out as described previously (see above AMIN et al.
reference).
A second mutant, IN20, whose promoter sequence also contains regions 1 and 2 was constructed from IN10, the DNA of which was partially digested with Bgl II (to cut the Bgl II linker between regions 1 and sticky ends were filled in as before, and a Sma linker (CCCGG) was added. The sequence modification therefore involved inserting new base pairs between the two concensus sequences of A hybrid test gene R5a, which contains a promoter with one region 1 and two copies of region 2 was constructed as follows: DNA was digested with Xho I, ends were filled in, the DNA subsequently digested with Hind III, and a 6.1 Kb fragment containing the hs promoter region, the 8-galactosidase gene and 3' trailer sequences was isolated from a low melting agarose gel. This fragment was ligated to a 2.6 Kb Bgi II/Hind III fragment from IN10 which included promoter region 2 and upstream vector sequences.
Then hybrid genes R6a and R7a which contain promoters with one unit of region one and three or four copies of region 2 were made as follows: DNA was digested with Pst I and partially with Xho I. The resulting 200 and 250 bp long hs promoter fragments were isolated electrophoretically. A 1.7 kb Sma I/Pst I fragment (which included two copies of region 2 and upstream vector sequences) and a 6.9 Kb Pst I fragment (contained part of the hs RNA leader region, the -galactosidase gene, 3' trailer and vector sequences) from R5a were isolated and ligated to the above promoter fragments.
Further mutants SEi to SE12 containing promoters with different numbers of synthetic consensus-like sequences were also constructed: A synthetic linker AGAAGCTTCT (New England Biolabs, custom-synthesized) was preligated and then ligated to Xho I-digested and blunt-ended
DNA.
i. WO 87/00861 PCT/EP86/00451 14 The structures of all plasmids were verified by extensive restriction analysis. Important regions of many constructs were sequenced (using the method of MAXAM and GILBERT, PNAS. USA 74 (1977), 560 564). Key promoter sequences showing the number and the position of the consensus like sequences are illustrated hereafter.
Expression experiments were carried out as follows: In the experiments described here, the different constructs were introduced into Drosophila melanogaster S3 cells by DEAE-dextran-mediated transfection as described previously (LAWSON et al., Mol. Gen. Genet. 198 (1984), 116 124). The transient synthesis of the common product of all hybrid genes used, an E. coli-specific P -galactosidase, was measured one day after transfection. A heat-shock, usually at 36.5 0 C, was applied prior to the preparation of cytoplasmic extracts and measurements of 0 -galactosidase activities.
The activities of mutants SE1 12, which only contain synthetic consensus-like sequence elements in their promoters, were assayed following a 2 hrs heat-shock at 36.5 0 C or following incubation of the transtected cells for the same length of time at 25 OC the control temperature. It was found that the activities of the hybrid genes are clearly a function of the number of copies of the synthetic consensus-like sequence present in their promoter regions. Significant heat-regulated activity could only be measured with mutants containing promoters with at least 3 sequence elements.
Mutant SE7, containing seven sequence elements, is considerably more active in heat-shocked cells than the control gene TN20 which contains a promoter of a 70KDa hsp gene which includes regions 1 and 2.
Similar results were experienced with hybrid test genes R5a, R6a and R7a (see Experimental part) the promoters of which contains two, three or four copies of region 2, respectively. The results indicated that promoters with two or more copies of region 2 are significantly more active than that of the control gene.
The invention is further illustrated by the following experimental details.
CONSTRUCTION OF PLASMID P17 A human hs 70 KDa gene was isolated as follows from a phage lambda human genomic library (LAWN et al., Cell 15 (1978), 1157-1174). The library is screened by plaque hybridization (BENTON and DAVIS, Science 196, (1977) WO 87/00861 1PCT/EPS6/00451 180-182) using as a probe a 2 Kb Sal I fragment from plasmid Sal 0 (KARCH et al., J. Mol. Biol. 148, (1981), 219-230) which contains the entire coding sequence for the Drosophila hs70 protein; any other isolate of this coding sequence can be used in place of plasmid Sal 0 as long as it contains regions of adequate practical homology to the human hsp70 gene. This cloning procedure is possible due to the high degree of conservation of the protein-coding sequences of the hs genes during evolution from Drosophila to man (VOELLMY et al., J. Biol. Chem.258 (1983) 3516-3522). Positively hybridizing clones are grown up and their DNA subjected to extensive sequence analysis. The presence of functional human hs control elements in the isolated DNAs is determined in a procedure analogous to that described for identification of Drosophila hs control hybrid plasmids in which the Escherichia coli B-Galactosidase gene was placed under hs control (EP 0.118.393). The hs controlled hybrid plasmids were identified in transient expression experiments using microinjection into Xenopus oocyte nuclei (VOELLMY et al., PNAS. USA 79 (1982) 1776-1780). One plasmi.d identified using such procedures as carrying human hs control sequences is plasmid pl7, fig. la, see VOELLMY et al., PNAS USA (1985), 4949-4953).
In the following section a series of plasmid constructs were prepared in which a c-DNA copy of the sequence encoding human growth hormone is placed under the control of a human hsp70 control sequence.
CONSTRUCTION OF p17 hGH dhfrA 6 Plasmid p17 was digested with EcoR I, filled in with DNA polymerase A Klenow fragment, and further digested with H-ind III. A 3.26 Kb fragment containing a human 3.15 Kb non transcribed sequence and an RNA leader sequence of 115 bp was purified. A Pvu II Hind III fragment from fig. Ib (New England Lai ratories) was also purified. The two fragments were ligated to give p' .mid p17 65 JO. This latter plasmid was digested with Bgl II and partiall with BamH I. A 3.4 Kb fragment was purified and "auto" ligated. This new plasmid p17 JO contains a small 5' non transcribe sequence of 0.5 kb and the above mentioned RNA leader sequence.
A human growth hormone c-DNA clone contained in a BamH I fragment was inserted into the BamH I site of the pSP65's polylinker to give plasmid pSP hGH.
Plasmid pSP hGH was then digested with Hind III and Sac 1 and the hGH sequence was inserted in the same restriction site of the polylinker ot p17 JO to give pl7hGH, (fig. 2c). In this plasmid construction the hGH sequence WO 87/00861 PCT/EP86/00451 16 was separated from hs sequences by 27 bp, and the sequence before the initiation site was... TC TAG AGG ATCC ATG The p17 hGH was digested with Xba I and Nco I and filled in with DNA polymerase Klenow fragment, allowing a specific deletion of six nucleotides.
The "auto" ligation allowed the construction of plasmid p17 hGH A6 which contains the hGH sequence under the control of the human hs promotor with a potentially modified and "strong" initiation site CTAGCATGG. This sequence conforms closely to the established concensus sequence that has been described for strong eukaryotic translation initiation sites. See the following references for details: M. KOZAK Nucl Acid Res, 9 (1981) 5232-5252 M. KOZAK Nucl Acid Res, 12 (1984) 857-872 M. KOZAK Nature, 308 (1984) 241-246 Finally p17 hGHA 6 was digested with EcoR I and BamH I. The 1.2 Kb fragment containing hGH and hs sequence was inserted by ligation into the BamH I and EcoR I sites of pSV2-dhfr (SUBRAMANI et al., Mol. Cell Biol. 1 (1981) 854-864).
The resulting plasmid pl7hGH dhtra 6, included firstly the hGH sequence under the control of the human hs promotor, and terminated by the late terminator sequence and, secondly, the dhfr gene under the control of the SV40 early promotor.
Construction of plasmid pl7hGH NEO Plasmid pSV2-NEO, 10 pg, (SOUTHERN BERG, J. Mol. Appl. Genet, 1 (1982), 237-341) was digested with BamH I and partially with Pvu II. The fragment containing the neomycin-resistance gene under the control of the early SV40 promotor and ended by the early SV40 terminator (including the poly A-addition site) was ligated with a Pvu II BamH I fragment derived from pSP 65, to give plasmid pSP NEO 9.
Plasmid p17 hGH, 5 ug, was digested with EcoR I. The resulting fragment of 1.3 Kb was purified and ligated with pSP N0O 9 "linearized" by EcoR I and treated with phosphatase.
The resulting plasmid, p17 hGH NEO contains two transcription units, first the neomycin-resistance gene (as above) and secondly, the hGH gene under the control of the human hs promoter and ended by the late WO 87/00861 PCT/EP86/00451 17 terminator (including the poly A-addition site). The initiation sequence is unmodified in this plasmid. The scheme used for these plasmid constructions are indicated graphically in figures la to 4c.
Expression Experiments In this first series of expression experiments we have used the transient expression system of injection of DNA constructs into Xenopus oocyte nuclei as previously describe- (VOELLMY and RUNGGER, P.N.A.S. USA 79 (1982) 1776-1780) to analyse the controlled synthesis of human growth hormone, using the plasmid constructions described in the above specifications. In brief, 2-5 ng of DNA in a volume of 10 nl was used for the injection of XenoDus oocytes. Ten minutes after microinjection; th oocytes were subjected to a heat-shock of 90 minutes at 36 0 C followed by incubation at 21 0 C for 12 hours in the presence of 35 S-labelled methionine (500 Ci/ml; 200 ul for 10-20 oocytes). The presence of labelled protein products in either the cytoplasmic extract of the oocytes, or in the suspension media was determined by immunoprecipitation of the extracts using rabbit anti hGH antisera (obtained from Dako Corporation, Santa Barbara, California; cat.
no A570). The detailed procedure tor immunoprecipitation and acrylamide gel electrophoretic analysis are essentially as previously described (EP- 0.118.393), the results obtained are shown in fig. In addition to the protein molecular weight markers indicated in lanes M, two series of analyses of immunoprecipitated proteins are shown; lanes 1-9 indicate the results obtained from the cytoplasmic extracts of the injected oocytes, while the lanes 10-18 show the corresponding results obtained by immunoprecipitation of the suspension media of the same oocytes. The results obtained concerning hGH synthesis are essentially identical for the two series of analyses, and the results of the secreted, extracellular proteins will be described in detail here.
Lane 10, using a comparable construction to pl7 hGH, but placing chicken lyosozyme gene sequence (KRIEG et al., J. Mol. Biol. 180, (1984) 615-643) under human hs control, no specific protein bands after precipitation with the anti hGH sera, even after the cells have been subjected to a heat shock as described above. Lanes 11 and 12 show the results using plasmid p17 hGH at the control and heat-shock temperatures respectively; lanes 13 and 14, 15 and 16, 17 and 18 are comparable experiments employing plasmids p17 hGHA 6; p 1 7 hGH dhfrA 6; and p17 hGH NEO. The results may be summarized with respect to the production of a protein of molecular weight WO 87100861 PCT/EP86/00451 18 21 KDa, specifically immunoprecipitated by the anti hGH sera, as follows: The plasmid p17 hGH, which is an RNA leader fusion construct within the RNA leader sequences derived from the human hsp70 clone and lacking five nucleotides of the human sequence, produces a detectable level of hGH after heat-shock, with no apparent synthesis in the absence of heat-shock.
Plasmid p17 hGHA 6 is a 5' untranslated sequence modification that provides a theoretically stronger ribosome binding site; this plasmid is seen to behave in a manner comparable to the previous one in the transient expression assay employed. It should be remembered that both of these plasmid constructions lack a classical 3' end terminator and poly A addition signal. Plasmid pi7 hGH NEO incorporates such a 3' modification by the insertion of the neomycin-resistance gene in an inverted mode with respect to the hGH sequences, and this with the unmodified initiation sequence; here a certain degree of increased efficiency of synthesis is observed. When the two types of 3' and 5' modifications are combined in plasmid construction p17 hGH dhfr A 6, a dramatic increase in expression efficiency of hGH is observed, and this being almost totally under heat-shock control (see lanes and 16, fig. As a demonstration of the generality of the modified hs control construct plasmid p17 hGH dhfr A6 was used to transfect cultures of COS-1 monkey cells (GLUZMAN, Cell 23, (1981) 175-182) using the CaC1 2 -DNA precipitation procedure (GRAHAM and VAN DER EBB, J. Virol., 52 (1973) 456-467).
The expression of hGH in these cells was analysed using procedures essentially as described elsewhere (EP-0.118.393). For the transfection of Chinese hamster ovary (CHO) cells, an analogous procedure was employed but the period of amplification used for the transfected plasmids in the COS cells system was omitted. Sixteen hours after transfection for the CHO cells, and fourty hours after for the COS cells, part of the cultures were subjected to a heat-shock ot 3 hours at 43 0 C followed by incubation at 37 0
C
for a further 16 hours in the presence of 35 S-methionine (100 pCi/ml; 2 7 cells). Control cutures that had not been heat-shocked were treated in a parallel fashion; both sets of cell cultures were then processed in the following way.
Briefly, cytoplasmic extracts were prepared using a treatment comprising the suspension of cells in NET buffer (EP-0.118.393) followed by gentle pipetting on ice and low speed centritugation; cell suspension cultures were simply clarified by a similar centrifugation step. Samples were then immunoprecipitated with anti hGH sera and analysed on acrylamide
_J
WO 87/00861 PCT/EP86/00451 19 gels as described above. The results obtained from analyses of the suspension cultures are shown in fig. 6.
The results obtained from the transfection of COS cells are shown in lanes 1, 2 and 3, and it can be seen that neither transfection with the control lysozyme construction followed by a heat-shock (lane or transfection with the optimal hGH construct in the absence of a heat-shock (lane give rise to the production and secretion of a specifically anti-hGH precipitated protein. The COS cells transfected with p17 hGH dhfr a6 and submitted to a heat-shock produce a single, major secreted protein band of the expected molecular weight (see lane An essentially identical result is obtained from the transfection studies using CHO cells, see figure 6, lanes 13, 14 and Preparation of mutants IN10, IN20, SE1 to SE12, R5a to R7a and R5b to R7b.
All the above plasmids were prepared according to the schemes disclosed heretofore employing usual means. The sequences of bases of some of the above mutant promoters regions modified according to the invention are listed below; in the formulae, the stars indicate the placement of the consensus sequences; The synthetic sequences were AGAAGCTTCT.
cctcgaggCTGCTCTCGTTGGTTCCAGAGAGCGCGAGATCTCGCGCCTCGAATGTTCGCGA (-48) cctcgaggCTGCTCTCGTTGGTTCCAGAGAGCGCGAGATCCCCGGGGATCTCGCGCCTCGAATGTTCGCGA cctcgaggCTGCTCTCGTTGGTTCCAGGAGCGCGAGTCtgagCTGCTCTCGTTGGTTCCAGAGAGCGCGAG
ATCCCCGGGGATCTCGCGCCTCGAATGTTCGCGA
WO 87/00861 PCT/EP86/004S I c czcgaggCTGCTCTCGTTGGTTCCAGAGAGCGCGAGATCCCCtcgaggCTGrCTCTCGTTGGTTCCAGAGAGCGC
GAGATCCCCGGGGATCTCGCGCCTCGAATGTTCGCGA
R6a cct cgaagCTGCTCTCGCTTGGTTCCAGAGAGCGCGAGATCtcgaggCTGCTCTCGTTGGTTCCAGAGAGCGCGAG ,r* ATCCCCt caaggCTGCTCTCGTTGGTTCCAGAGAGCGCGAGATCCCCGGGGATCTCGCGCCTCGAATGTTCGCGA R7a ct cgaggCTGCTCTCGTTCGTTCCAGAGAGCGCGAGATCt cgagqCTGCTCTCGTTGGTTCCAGAGAGCGCGAG C it* 7h 7 ATLCCCCtLCgaggCTGCTCTCGTTGGTTCCAGAGAGCGcGAGATCt cgaggCTGCTCTCGTTGGTTCCAGAGAGC GCGAGATCCCCGGGGATCTCGCGCCTCGAATGT TCGCGA SE7 cc t cgaAGAAGCTTCTAGAAGCTTCTAGAAGCTTCTAGAAG .TAGAAGCTT CTAGAAGCTTC TAGAAGCTTCTtcgaggCGA Expression experiments: As already mentioned betore, the different construct involving the consensus sequence and copies thereof were tested in Drosophila S3 cells after transfection by the DEAE-dextran technique of LAWSON et al., Mol.
Gen. Genet. 198 (1984), 116-124.
The activities of mutants SE. 12, which only contain synthetic consensus-like sequence elements in their promoters, were assayed following a 2 hrs heat-shock at 36.5 0 C or following incubation of the transfected cells for th~e same length of time at 25 OC, the control temperature. The results of these experiments are presented in Table 1.
~0
J
WO 8710361 F /OTIEP86/00451 21 TABLE 1 Mutants Nb. of sequence elements B Galactosidase (relative units) Heat induced Control SE1 SE2 SE3 SE7 SE9 SE12 2 (control) 1 2 3 7 9 12 1.00 0.05 0.10 0.45 1.80 0.65 0.80 0.00 0.05 0.00 0.00 0.05 0.05 0.00 The activities of the hybrid genes are clearly a function of the number of copies of the synthetic consensus-like sequence present in their promoter regions. Significant heat-regulated activity could only be measured with mutants containing promoters with at least 3 sequence elements.
Mutant SE7, containing seven sequence elements, is considerably more active in heat-shocked cells than the control gene IN20 (this hybrid gene contains a promoter of a 70 KDa hsp gene which includes regions 1 and 2).
Similar experiments were carried out with heat-shock hybrid genes IN2*, R5a, R6a and R7a the promoters ot which contain one, two, three or four copies of region 2, respectively. Drosoohila cells that had been transfected with the hybrid genes were either exposed to a heat-shock at 36.5 0 C tor 90 or 120 min or were incubated further at 25 0 C. To exclude the possibility that differences in the activities of th. promoters would be obscured by slower post-transcriptional event, transcription was stopped (with actinomycin D) after 15 to 45 min of heat-shock while translation was allowed to continue to the end of the heat treatment. The results of these experiments (Table 2) strongly suggest that promoters with two or more WO 87/00861 PCT/EP86/00451 22 copies of region 2 are three to five times more.active than that of the control gene (IN20) which only contains one copy of this region. Again, it was observed that all constructs are perfectly heat-inducible: they are essentially inactive at the control temperature of 25 0
C.
However, at 34 0 C constructs R5a and R6a were found to be expressed at elevated levels. It should be mentioned that IN20 activity is only barely detectable at 34 0 C. Thus modifications in heat-shock promotor sequences can lower the threshhold of stress induction, i.e. induction temperature in this case, while remaining totally inactive at the control temperature.
These results indicate a minimal heat-shock regulatory sequence as CTCGnnnnTTC. Comparison to Drosophila hsp 84 promotor sequences suggests that the inverted repeat of CTCG, i.e. CGAG is also an acceptable part of heat-shock consensus elements (Holmgren et al., PNAS USA. 78 (1981) 3 775- 3778).
I -IIXl~r; WO 87/00861 PCT/EP86/00451 23 TABLE 2 Treatments of cells Galactosidase activity (rel. units) R6a R7a Incubation at 25 0 C 0.00 0.05 0.05 Incubation at 340C 0.20 1.50 for 2 hours Incubation at 36.50C 0.30 1.20 1.40 for 2 hours, actinomycin D added after min of incubation at high temp.
ditto, actinomycin 1.00 4.00 3.35 added after 30 min Incubation at 25 0 C 0.00 0.00 Incubation at 34 0 C 0.20 1.05 for 2 hours Incubation at 36.5 0 C 1.00 3.55 for 90 min, actinomycin D added after min These experiments demonstrate that significant promoter activity requires the presence of multiple consensus-like sequences, and that promoters with higher activities than the natural ones can be constructed. It is important to note that heat-inducibility is maintained in the synthetic promoters irrespective of the number of consensus-like sequences.
The experiments described here show that the performance of natural heat-shock gene promoters can be improved by in vitro sequence manipulation WO 87/00861 PCT/EPS6/00451 24 of these promoters. It has been demonstrated here that the maximal activity as well as the activity at suboptimal temperatures of a Drosophila heatshock consensus-like sequences are located near the start ot transcription site of the heat-shock gene.
Interestingly, it appears that the addition of a third consensus-like sequence to a promoter of a Drosophila 70 KD hsp gene including regions 1 and 2 has a more significant effect than the subsequent addition of a forth or fifth element (Table 2).
Although we have not systematically tested effects of the distance between the newly added heat-shock elements and the downstream promoter elements on promoter activity, the experiments presented here suggest the importance of this parameter. Addition of a third heat-shock consensus sequence in R5a increases promoter activity substantially (see results in Table A third element is located about 100 bp upstream from the second element in the natural Drosophila promoter (see region 3 in Fig. Removal of this third element has been reported not to affect significantly the activity of the promoter (AMIN et al., Mol. cell. biol 5 (1985) 197-203).
It thus appears that the natural third element may be too far away from downstream promoter sequences to play an important role in promoter function.
Given the evolutionary conservation of the heat- shock response, it can be assumed that similar manipulations will also improve the pertormance of heat-shock promoters isolated from other eukaryotic organisms in eukaryotic cells (from Drosophila, man, or other eukaryotic organisms).
Combinations of sequence variants comprising heat-shock promotor, RNA leader, translation initiation and non-translated sequences can be assumed under certain combinations to provide optimal heat-shock expression levels of genes of interest.
Plasmids of interest have been deposited at the National Collections of Industrial Marine Bacteria Ltd.
Aberdeen, Scotland, as follows Microorganism Strain number NCIB number Escherichia coli HB101 pl7 hGH.NEO 12122 Escherichia coli HBi01 p17 hGH 12123 Escherichia coli HblOl p17 hGH dhfr a6 12124 Escherichia coli HB101 p17 hGH a6 12125
Claims (22)
1. A method for enhancing the heat inducible expression of proteins of eukaryotic genes of interest placed in eukaryotic host cells, this method comprising the steps of a) providing a recombinant gene construct in which a gene of interest is functionally linked under the expressional control of a eukaryotic heatshock promoter element, and which includes one or more non translated expression control sequences 5' and, optionally, 3' to said gene of interest, some modifications being introduced into said 5' non translated sequences which essentially consist of increasing in said promoter the number of heatshock consensus sequences originally 9 present and/or deleting base-pairs adjacent to the translation initiator; said the heatshock gene promoter sequence comprising not more than 1500 deoxynucleotides and from 2 to 12 heatshock promoter consensus regions, each said heatshock promoter consensus region comprising not more than 11 deoxynucleotides or formula substantially approaching 1 2 3 4 5 6 7 8 9 10 11 T C C G A G n 1 n 2 n 3 n 4 T T C such that at least 5 deoxynucleotides in the formula in positions 1 to 4, and 9 to 11, are substantially conserved from heatshock promoter consensus region to heatshock promoter consensus region, and wherein each nucleotide is independently selected from A, T, C, or G, the sequence coding for translation initiation comprising 25 U24U/e/NNG not more than 20 deoxynucleotides and substantially comprising the formula -4 -3 -2 -1 1 2 3 4 nx C C A C C A T G G n(y-x) wherein ATG is the translation initiation codon, wherein CC and CC predominates the positions -2 and -5 at an occurrence frequency of at about 80%, wherein ATG predominates in positions 1, 2 and 3 at an occurrence frequency of about 90%, wherein G predominates in position 4 at an O occurrence frequency of 40-60%, wherein each nucleotide is independently selected from A, T, C, or G, wherein y is selected from 0 to 11, wherein x is selected from 0 to y, all changes in the above being understood to closely resemble consensus sequence described for strong eukaryotic translation, the optional non-translated sequence at the 3' end *0* comprising non-translated gene sequences of not more than 3000 deoxynucleotides, a terminator sequence, and a poly A addition sequence; and b) introducing said gene construct with said modifications S into host cells of eukaryotic origin and subjecting cultures of these cells to heatshock, whereby the expression of said recombinant gene to proteins of interest upon induction by heat is enhanced. 26 _j U240e/NNG
2. The method of claim 1, in which 3' non translated seqences are taken from terminator genes of heatshock protein genes or foreign genes.
3. The method of claim 1, in which said consensus sequences which regulate the expression of the heatshock protein genes have formula approximating CnnGAAnnTTCnnG where the base of each nucleotide is independently selected from A, T, C or G.
4. The method of claim 3, in which the number of consensus sequences is three or more and the separation between the e"*e second and the third consensus sequence has been set to less than 100 base pairs.
5. A combination of a eukaryotic host-cell carrying a S* recombinant gene construct, wherein the recombinant gene construct comprises: a) a gene of interest; b) a heatshock protein gene promoter element of eukaryotic origin for inducibly controlling the expression of said gene of interest; c) 5' and optionally 3' non-translated sequences with modifications which consist of nucleotide or sequence deletion, insertion or substitution for improving the efficiency of the inducible expression of the genes of interest and in which the 0 said recombinant gene is incorporated in order to express the protein product of the said gene upon induction by heat; said the heatshock gene promoter sequence comprising not more than 1500 deoxynucleotides and from 2 to 12 heatshock promoter consensus regions, each said heatshock promoter consensus region comprising not more than 11 deoxynucleotides 27 o IN 40 o C) 0-i F Y^ '~ir? .:i a~ K 0240e/NNG or formula substantially approaching 1 2 3 4 5 6 7 8 9 10 11 T C C G A G n 1 n 2 n 3 n 4 T T C such that at least 5 deoxynucleotides in the formula in positions 1 to 4, 9 to 11, are substantially conserved from heatshock promo'ar consensus region to heatshock promoter consensus region, and wherein each nucleotide is independently selected from A, T, C, or G, the sequence coding for translation initiation comprising not more than 20 deoxynucleotides and substantially comprising the formula -5 -4 -3 -2 -1 1 2 3 4 n x C C A C C A T G G n(y-x wherein ATG is the translation initiation codon, wherein CC and CC predominates the positions -2 and -5 at an occurrence frequency of at about 80%, wherein ATG S* predominates in positions 1, 2 and 3 at an occurrence frequency of about 90%, wherein G predominates in position 4 at an occurrence frequency of 40-60%, wherein each nucleotide is independently selected .from A, T, C, or G, wherein y is selected from 0 to 11, wherein x is selected from 0 to y, all changes in the above being understood to closely resemble consensus sequence described for 1 strong eukaryotic translation, the optional non-translated sequence at the 3' end comprising non-translated gene sequences of not more than 3000 28 0240e/NNG deoxynucleotides, a terminator sequence, and a poly A addition sequence.
6. A recombinant gene/host-cell combination as defined in claim 5, whereip the gene expression unit is derived from human genomic DNA.
7. A recombinant gene/host-cell combination as defined in claim 5, wherein the gene expression unit is derived from the heatshock genes of eukaryotic origin.
8. A recombinant gene/host-cell combination as defined in claim 5, wherein the gene expression unit is derived from the 70kd heatshock genes isolated from human genomic DNA.
9. A recombinant gene/host-cell combination as defined in S o claim 5, wherein the DNA construct further comprises a selectable and/or amplifiable genetic marker.
Plasmid pl7hGHA6 as hereinbefore defined as a new composition of matter.
11. Plasmid pl7hGH dhfr A6 as hereinbefore defined as a new .00. composition of matter.
12. Plasmid pl7hGH NEO as hereinbefore defined as a new composition of matter.
13. Mutant plasmids SE1, SE2, SE3, SE7, SE9, SE12, R6a, R7a as hereinbefore defined as new compositions of matter.
14. A method for inducing the expression of a gene coding for the production of a protein of interest under the control of a heatshock gene promoter comprising: assembling sequences of deoxynucleotides into recombinant DNA to be inserted into a plasmid comprising, successively, in a 5' to 3' direction: a heatshock gene 29 ?0H v- 0240e/NNG promoter sequence, a transcription start site sequence, a transcribed but not translated leader sequence for subsequent translational control in protein production, a sequence coding for translation initietion, a coding sequence for the production of a protein of interest and a non-translated sequence at the 3' end, the heatshock gene promoter sequence comprising not more than 1500 deoxynucleotides and from 2 to 12 heatshock promoter consensus regions, each said heatshock promoter consensus region comprising not more than 11 deoxynucleotides *O* or formula substantially approaching 1 2 3 4 5 6 7 8 9 10 11 T C C G A G nl n 2 n 3 n 4 T T C such that at least 5 deoxynucleotides in the formula in positions 1 to 4, and 9 to 11, are substantially conserved from heatshock promoter consensus region to heatshock promoter consensus region, and wherein each nucleotide is independently selected from A, T, C, or G, the sequence coding for translation initiation comprising ea, not more than 20 deoxynucleotides and substantially comprising the formula -4 -3 -2 -1 1 2 3 4 n x C C A C C A T G G n(y_ wherein ATG is the translation initiation codon, wherein CC and CC predominates the positions -2 and -5 at an occurrence frequency of at about 80%, wherein ATG 30 0240e/NNG predominates in positions 1, 2 and 3 at an occurrence frequency of about 90%, wherein G predominates in position 4 at an occurrence frequency of 40-60%, wherein each nucleotide is independently selected from A, T, C, or G, wherein y is selected from 0 to 11, wherein x is selected from 0 to y, all changes in the above being understood to closely resemble consensus sequence described for strong eukaryotic translation, the non-translated sequence at the 3' end comprising non-translated gene sequences of not more than 3000 deoxynucleotides, a terminator sequence, and a poly A addition sequence, inserting the fragment into a plasmid so as to form a heatshock gene promoter controlled plasmid, inserting the heatshock gene promoter controlled plasmid into a eukaryotic cell competent in the expression of the gene coding for the production of the protein, stressing the eukaryotic cell to induce expression o. f the gene coding for the production of the protein.
The method according to claim 14 wherein the heatshock gene promoter is derived from the genomic DNA of Drosophila 0* Smelanogaster.
16. The method according to claim 15 wherein the genomic DNA is the genes encoding the 70 kilodalton heat-shock proteins of Drosophila melanogaster.
17. The method according to claim 14, in which the sequences of deoxynucleotides of step further comprises a sequence 31 U24Ue/\JJNJ coding for a selectable marker for enabling selection of transformant plasmids.
18. The method according to claim 17 wherein the selectable marker is antibiotic resistance.
19. A method of enhancing the heat inducible expression of proteins of eukaryotic genes of interest placed in eukaryotic host-cells substantially as herein described with reference to any one of the examples, excluding control examples.
A combination of a eukaryotic host-cell carrying a recombinan gene construct substantially as herein described with reference to any one of the examples, excluding control examples.
21. Proteins which have been expressed according to the method defined in any one of claims 1 to 4 or 19.
22. Genes which have been expressed according to the method defined in any one of claims 14 to 18. *0*O DATED this 13th day of August, 1990. BATTELLE MEMORIAL INSTITUTE By Its Patent Attorneys ARTHUR S. CAVE CO. 32
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP85810354 | 1985-07-31 | ||
EP85810354 | 1985-07-31 |
Publications (2)
Publication Number | Publication Date |
---|---|
AU6286086A AU6286086A (en) | 1987-03-05 |
AU604214B2 true AU604214B2 (en) | 1990-12-13 |
Family
ID=8194647
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU62860/86A Ceased AU604214B2 (en) | 1985-07-31 | 1986-07-29 | An improved heat-shock control method and system for the production of competent eukaryotic gene products |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0231368A1 (en) |
AU (1) | AU604214B2 (en) |
ES (1) | ES2003085A6 (en) |
WO (1) | WO1987000861A1 (en) |
ZA (1) | ZA865702B (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63502637A (en) * | 1986-02-06 | 1988-10-06 | ザ、ゼネラル、ホスピタル、コ−ポレ−ション | Inducible heat shock and amplification system |
WO1988001645A1 (en) * | 1986-08-26 | 1988-03-10 | Macquarie University | Transformation of an organism using antisense rna or promoter occlusion technique |
US5521084A (en) * | 1992-11-10 | 1996-05-28 | Biostar, Inc. | Bovine heat shock promoter and uses thereof |
JP2001501458A (en) | 1996-08-15 | 2001-02-06 | アメリカ合衆国 | Spatial and temporal control of gene expression using a combination of heat shock protein promoter and local heating |
US7279565B2 (en) * | 1998-05-05 | 2007-10-09 | Richard Voellmy | Molecular regulatory circuits to achieve sustained activation of genes of interest by a single stress |
GB9905498D0 (en) * | 1999-03-11 | 1999-05-05 | Glaxo Group Ltd | Expression |
AT500838B1 (en) * | 2004-04-20 | 2007-11-15 | Veterinaermedizinische Uni Wie | MULTIPLE HSE |
ITUB20153898A1 (en) * | 2015-09-25 | 2017-03-25 | Univ Degli Studi Di Palermo | INTELLIGENT LABELS FOR VISUAL DETERIORATION OF THE DETERIORATION OF FOOD PRODUCTS |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0159884A2 (en) * | 1984-04-13 | 1985-10-30 | Lubrizol Genetics Inc. | Heat shock promoter and gene |
EP0165759A2 (en) * | 1984-06-11 | 1985-12-27 | Cetus Corporation | Mammalian promotors useful in yeast expression |
AU572113B2 (en) * | 1983-02-07 | 1988-05-05 | Battelle Memorial Institute | Compositions for expression of competent eukaryotic gene products |
-
1986
- 1986-07-29 WO PCT/EP1986/000451 patent/WO1987000861A1/en not_active Application Discontinuation
- 1986-07-29 EP EP86905251A patent/EP0231368A1/en not_active Withdrawn
- 1986-07-29 AU AU62860/86A patent/AU604214B2/en not_active Ceased
- 1986-07-30 ES ES8600725A patent/ES2003085A6/en not_active Expired
- 1986-07-30 ZA ZA865702A patent/ZA865702B/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU572113B2 (en) * | 1983-02-07 | 1988-05-05 | Battelle Memorial Institute | Compositions for expression of competent eukaryotic gene products |
EP0159884A2 (en) * | 1984-04-13 | 1985-10-30 | Lubrizol Genetics Inc. | Heat shock promoter and gene |
EP0165759A2 (en) * | 1984-06-11 | 1985-12-27 | Cetus Corporation | Mammalian promotors useful in yeast expression |
Also Published As
Publication number | Publication date |
---|---|
AU6286086A (en) | 1987-03-05 |
ZA865702B (en) | 1987-03-25 |
ES2003085A6 (en) | 1988-10-16 |
EP0231368A1 (en) | 1987-08-12 |
WO1987000861A1 (en) | 1987-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hayashi et al. | Lens-specific enhancer in the third intron regulates expression of the chicken delta 1-crystallin gene. | |
AU692196B2 (en) | Translational enhancer DNA | |
Yanagida et al. | A novel cis-acting DNA element required for a high level of inducible expression of the rat P-450c gene | |
Birchmeier et al. | Generation of authentic 3′ termini of an H2A mRNA in vivo is dependent on a short inverted DNA repeat and on spacer sequences | |
US4840896A (en) | Heteropolymeric protein | |
Digard et al. | Complex formation between influenza virus polymerase proteins expressed in Xenopus oocytes | |
Masayuki et al. | The promoter elements of the mouse myelin basic protein gene function efficiently in NG108-15 neuronal/glial cells | |
Ingraham et al. | Characterization of two atypical promoters and alternate mRNA processing in the mouse Thy-1.2 glycoprotein gene | |
Rak et al. | Expression of two proteins from overlapping and oppositely oriented genes on transposable DNA insertion element IS 5 | |
EP0118393B1 (en) | Methods and compositions for expression of competent eukaryotic gene products | |
EP0160699A1 (en) | Production of heterodimeric human fertlity hormones. | |
CA1341095C (en) | Cdna coding for the human von willebrand factor, plasmids or phages with such a cdna coding or fragments thereof respectively, micro-organisms and animal or human cell which contain such plasmids or phages, preparation of proteins by the cultivation of the above mentioned hosts, the obtained proteins and pharmaceutical compositions containing a biologically | |
EP0377676A1 (en) | Human erythroid-specific transcriptional enhancer. | |
AU604214B2 (en) | An improved heat-shock control method and system for the production of competent eukaryotic gene products | |
Eliceiri et al. | Stable integration and expression in mouse cells of yeast artificial chromosomes harboring human genes. | |
Gruss et al. | Synthesis of stable unspliced mRNA from an intronless simian virus 40--rat preproinsulin gene recombinant. | |
D'Amore et al. | Complete sequence and organization of the murine. beta.-glucuronidase gene | |
Ruether et al. | Cell-type-specific synthesis of murine immunoglobulin μ RNA from an adenovirus vector | |
US4939088A (en) | Sustained production of recombinant gamma interferon using an Epstein-Barr virus replicon | |
AU669713B2 (en) | Constitutive and inducible epidermal vector systems | |
US5486462A (en) | Differentiative expression modules | |
Mous et al. | Stimulation of sea urchin H2B histone gene transcription by a chromatin-associated protein fraction depends on gene sequences downstream of the transcription start site | |
Wise et al. | Aberrant expression of platelet-derived growth factor A-chaln cDNAs due to cryptic spiking of RNA transcripts In COS-1 cells | |
Ozawa et al. | Cloning of an alternative form of plakoglobin (γ-catenin) lacking the fourth armadillo repeat | |
NZ506941A (en) | Self-regulated apoptosis of inflammatory cells by gene therapy |